Overview

At a Glance

  • PCT: growing business providing development, manufacturing and delivery of cell-based therapies
              - Averaging 25% year-over-year revenue growth over past two years
              - Unmatched cell and cell-based gene therapy-specific experience and expertise
              - Expansive list of noteworthy cell and cell-based gene therapy clients
  • Focused pipeline of highly promising cell therapies
              - Leverages internal specialized cell therapy clinical development expertise and PCT’s CMC prowess
              - Partnering post-POC provides value inflection and an additional stream of new PCT clients
              - CLBS03 – Treg cell therapy targeting adolescents with recent-onset type 1 diabetes
  • Highly experienced management and domain-specific scientific team

Webcasts

Caladrius CEO, Dr. David Mazzo, presented at the Noble Financial Capital Markets on January 18, 2016, at 4:30 pm Eastern time.
The webcast will be available from market-open on January 22, 2016 at http://clbs.bio/Noble2016. An archive of the webcast will be available on the website for 90 days.

Company management hosted a conference call to discuss their recent announcement of strategic refocus on January 7, 2016, at 8:30 am Eastern time.
To access an archive of the call visit https://engage.vevent.com/rt/caladriusao~010516. The archived call will be available on the website for 90 days.


Stock Chart

Maximum 30 minute delay for quote.

Sign up to our e-mail list to receive Caladrius announcements.


  • SC-Conference-Logo

    Source Capital Group 2016 Disruptive Growth & Healthcare Conference

    • Venue: Convene, New York, New York
    • Website: http://clbs.bio/1n6TlDD
    • Date and Time: Wednesday, February 10, 2016, 12:30 PM ET
    • Presenter: Joseph Talamo, Senior Vice President and Chief Financial Officer, Caladrius Biosciences
    • Topic: Company Presentation
  • BIO-CEO-Investor

    BIO CEO & Investor Conference 2016

  • Novel-CV-Therapeutics-Summit-2015-Logo-e1440586258298

    Novel Cardiovascular Therapeutics Summit

    • Venue: Hotel Nikko San Francisco, San Francisco, California
    • Website: ncvt-summit.com
    • Date and Time: Thursday, January 28, 2016, 3:30 PM ET
    • Presenter: Douglas Losordo, Chief Medical Officer and Senior Vice President, Clinical, Medical and Regulatory Affairs, Caladrius Biosciences
    • Topic: Cell Based Therapy for Cardiovascular Disease: A single treatment for long-term modification of disease natural history
  • Phacilitate_2016

    Phacilitate Cell and Gene Therapy World Conference

    Phacilitate Cell and Gene Therapy World Conference

    Session 1

    • Date and Time: Monday, January 25, 2016, 12:50 PM ET
    • Presenter: Brian Hampson, Vice President, Global Manufacturing Sciences and Technology, PCT
    • Topic: Patient-specific cell therapy factory of the future – can you get there from here?

    Session 2

    • Date and Time: Monday, January 25, 2016, 3:55 PM ET
    • Panelist: Robert Preti, Senior Vice President, Manufacturing and Technical Operations and Chief Technology Officer, Caladrius Biosciences; President, PCT
    • Topic: What does commercialization look like?

    Session 3

    • Date and Time: Tuesday, January 26, 2016, 4:00 PM ET
    • Presenters: Robert Preti, Senior Vice President, Manufacturing and Technical Operations and Chief Technology Officer, Caladrius Biosciences; President, PCT; Brian Hampson, Vice President, Global Manufacturing Sciences and Technology, PCT; Ian Gaudet, Director, Innovation & Engineering, PCT
    • Topic: Getting Commercial: Engineering the Future
  • NobleCon12Logo

    Noble Financial Capital Markets 12th Annual Investor Conference


Investor Relations Contact


Lippert/Heilshorn & Associates
Anne Marie Fields
Phone: +1-212-838-3777
E-mail: afields@lhai.com

Media Contact


Caladrius Biosciences, Inc.
Eric Powers
Director of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@caladrius.com